Abstract: The present invention relates to a heat cabin with hot air extraction. In particular, it relates to a heat cabin (10) which is equipped with a heat supply and an exhaust air system, wherein the heat cabin (10) comprises support beams (42) and cladding panels (40) and the cladding panels (40) are aligned perpendicular to a wall or ceiling normal, and the exhaust air system comprises exhaust air openings (50) in the cladding panels (40), whose shape is determined by the support beams (42) and/or the cladding panels (40) and which have no through passage parallel to the wall or ceiling normal. Furthermore, it relates to a method for operating a heat cabin.

Abstract: An optical diode (1) comprising an optical wave guide for guiding light, preferably of a light mode, with a vacuum wavelength ?0, wherein the optical wave guide has a wave guide core (2, 3, 14) with a first index of refraction (n1), and the wave guide core (2, 3, 14) is surrounded by at least one second optical medium which has at least one second index of refraction (n2), wherein n1>n2 applies, wherein the wave guide core (2, 3, 14) has at least in sections a smallest lateral dimension (7) which is a smallest dimension of a cross section (6) perpendicular to a propagation direction (5) of the light in the wave guide core (2, 3, 14), wherein the smallest lateral dimension (7) is greater than or equal to ?0/(5*n1) and less than or equal to 20*?0/n1, wherein the optical diode (1) additionally comprises at least one absorber element (10, 11, 15, 16) which is arranged in a near field, wherein the near field consists of the electromagnetic field of the light of the vacuum wavelength ?0 in the wave guide core (2

Abstract: An optical diode (1) comprising an optical wave guide for guiding light, preferably of a light mode, with a vacuum wavelength ?0, wherein the optical wave guide has a wave guide core (2, 3, 14) with a first index of refraction (n1), and the wave guide core (2, 3, 14) is surrounded by at least one second optical medium which has at least one second index of refraction (n2), wherein n1>n2 applies, wherein the wave guide core (2, 3, 14) has at least in sections a smallest lateral dimension (7) which is a smallest dimension of a cross section (6) perpendicular to a propagation direction (5) of the light in the wave guide core (2, 3, 14), wherein the smallest lateral dimension (7) is greater than or equal to ?0/(5*n1) and less than or equal to 20*?0/n1, wherein the optical diode (1) additionally comprises at least one absorber element (10, 11, 15, 16) which is arranged in a near field, wherein the near field consists of the electromagnetic field of the light of the vacuum wavelength ?0 in the wave guide core (2

Abstract: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

Abstract: The present invention provides a method for preparation of a high concentration liquid formulation (HCLF) of an antibody or a fragment thereof. The present invention also relates to a method for stabilizing an anti-CD20 antibody or a fragment thereof in a liquid pharmaceutical formulation. Furthermore, the present invention relates to a liquid pharmaceutical formulation of a veltuzumab antibody or a fragment thereof comprising at least 155 mg/mL of a veltuzumab antibody or a fragment thereof.

Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Abstract: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.

Abstract: The present invention provides a method for preparation of a high concentration liquid formulation (HCLF) of an antibody or a fragment thereof. The present invention also relates to a method for stabilizing an anti-CD20 antibody or a fragment thereof in a liquid pharmaceutical formulation. Furthermore, the present invention relates to a liquid pharmaceutical formulation of a veltuzumab antibody or a fragment thereof comprising at least 155 mg/mL of a veltuzumab antibody or a fragment thereof.

Abstract: A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1 H-pyrazol-4-yl)-be?zenesulfonyl]-1 H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate.

Abstract: The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase.

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.

Abstract: A salt of (E)-N-{2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-be?zenesulfonyl]-1H-pyrrol-3-yl)-acrylamide selected from the group consisting of the hydrobromide, methansulfonate, hemi ethane-1,2-disulfonate, benzenesulfonate, toiuenesulfonate and 2-naphthalenesulfonate.

Abstract: The invention relates to novel peptides, which can be used for the production of pharmaceutical compositions. These pharmaceutical compositions can be used for the treatment of edema, in particular pulmonary edema.

Abstract: The present invention relates to amorphous ciclesonide, methods to prepare the same, pharmaceutical compositions comprising amorphous ciclesonide as active ingredient, and methods of treatment using amorphous ciclesonide.

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.